



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
APPLICATION NO.	FILING DATE		2462 122116	8702
10/018,875	03/22/2002	Midori Shima	2462-132US	0702
75	90 03/26/2003			
Richard C Woodbridge			EXAMINER	
Woodbridge & Associates PO Box 592			SWOPE, SHERIDAN	
Princeton, NJ 08542-0592			ART UNIT	PAPER NUMBER
			1652	
			DATE MAILED: 03/26/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No	, 	Applicant(s)				
•			SHIMA ET AL.				
Offic Action Summary	10/018,875		Art Unit				
Onic Action Summary	Examiner Shoridan I Sw	rone	1652				
The MAII INC DATE of this communication or	Sheridan L. Sw	er sheet with the co					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status 1) Responsive to communication(s) filed on							
	······································	-final.					
2) Since this application is in condition for alloy	wance except for	formal matters, pr	osecution as to the merits is				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4) Claim(s) 1-13 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) <u>1-13</u> are subject to restriction and/o	or election require	ement.					
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Applicant may not request that any objection to	ice all accer	neid in abeyance. S oved h\□ diseopre	oved by the Examiner.				
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner.							
, <u> </u>							
Priority under 35 U.S.C. §§ 119 and 120	ian priority under	· 35 U.S.C. & 119/2	a)-(d) or (f).				
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for dome	14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	4) 5) s) 6)	Interview Summa Notice of Informal Other:	ry (PTO-413) Paper No(s) I Patent Application (PTO-152)				

j...

Art Unit: 1652

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-3 and 10-13, in part, drawn to a serine protease inhibitor that binds to the substrate wherein said inhibitor is a mutated protease.

Group II, claim(s) 1, 2, and 10-13, in part, and 4, 5, 6, 7, and 8 drawn to a serine protease inhibitor that binds to the substrate wherein said inhibitor is an anhydridized serine protease.

Group III, claim(s) 1-3 and 10-13, in part, and 9, drawn to a serine protease inhibitor containing at least two types of substances that bind to the substrate.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature for the following reasons: The technical feature linking Groups I-III appears to be that they all relate to proteases inhibitors that act by binding to the protease substrate. However, Cook et al, 1995 teach an protein that binds to a thrombin receptor at the thrombin binding site, thereby inhibiting the ability of thrombin to bind, cleave, and activate said receptor. In addition, the inhibitors of Groups I-III do not have the same structure. Therefore Groups I-III share no special technical feature as defined by PCT Rule 13.2, they do not define a contribution over the prior art. Accordingly, Groups I-VIII are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.

Application/Control Number: 10/018,875

Art Unit: 1652

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheridan L. Swope whose telephone number is 703-305-1696. The examiner can normally be reached on M-F; 8:30-5 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy can be reached on 703-308-3804. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Sheridan Lee Swope

REBECCA E. PROUTY PRIMARY EXAMINER GROUP 1969